About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
Zacks Investment Research on MSN
FDA accepts SMMT's application seeking approval for NSCLC drug
Summit Therapeutics SMMT announced that the FDA has accepted its biologics license application (BLA) seeking approval for ...
BeyondSpring Inc. has announced its Q1 2025 financial results and provided an update on its clinical programs, highlighting the early efficacy of its drug Plinabulin in treating metastatic non-small ...
BeyondSpring presents Phase 2 data showing Plinabulin's potential in metastatic NSCLC after PD-1/L1 therapy, with promising survival rates. BeyondSpring Inc. announced promising interim results from ...
LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and ...
The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...
December 29, 2011 — Combining early palliative care with standard care can help optimize the timing of final chemotherapy administration and transition to hospice services. Overall, this resulted in ...
CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus chemotherapy over six years. The combination therapy was particularly ...
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...
New Study Introduces a Personalized Therapy Selection Approach in NSCLC Poised to Transform Treatment Decisions Cellworks Group Inc., a leader in Personalized Therapy Decision Support and ...
Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results